1. Home
  2. PROV vs CGTX Comparison

PROV vs CGTX Comparison

Compare PROV & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Provident Financial Holdings Inc.

PROV

Provident Financial Holdings Inc.

HOLD

Current Price

$17.14

Market Cap

103.7M

Sector

Finance

ML Signal

HOLD

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.88

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PROV
CGTX
Founded
1956
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
103.7M
94.5M
IPO Year
2009
2021

Fundamental Metrics

Financial Performance
Metric
PROV
CGTX
Price
$17.14
$0.88
Analyst Decision
Hold
Strong Buy
Analyst Count
2
3
Target Price
$16.25
$3.33
AVG Volume (30 Days)
9.6K
1.4M
Earning Date
04-27-2026
05-06-2026
Dividend Yield
3.26%
N/A
EPS Growth
N/A
62.79
EPS
0.47
N/A
Revenue
N/A
N/A
Revenue This Year
$4.14
N/A
Revenue Next Year
$3.70
N/A
P/E Ratio
$36.51
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$0.22
52 Week High
$17.20
$3.83

Technical Indicators

Market Signals
Indicator
PROV
CGTX
Relative Strength Index (RSI) 78.06 45.49
Support Level $15.66 $0.55
Resistance Level N/A $1.19
Average True Range (ATR) 0.24 0.13
MACD 0.12 0.00
Stochastic Oscillator 93.88 52.41

Price Performance

Historical Comparison
PROV
CGTX

About PROV Provident Financial Holdings Inc.

Provident Financial Holdings Inc is a holding company of Provident Savings Bank, F.S.B. It is a financial services company committed to serving consumers and small to mid-sized businesses in the Inland Empire region of Southern California. Its business activities consist of community banking, investment services and trustee services for real estate transactions. The group operates in Bank segment that include attracting deposits, offering banking services and originating and purchasing single-family, multi-family, commercial real estate, construction and, to a lesser extent, other mortgage, commercial business and consumer loans. Its evenues are derived from interest earned on its loan and investment portfolios, and fees generated through its community banking activities.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.

Share on Social Networks: